16.08.2023

To, National Stock Exchange of India Limited "Exchange Plaza", Bandra-Kurla Complex, Bandra (East) <u>Mumbai 400 051</u>

BSE Limited Floor- 25, P J Tower, Dalal Street, <u>Mumbai 400 001</u>

SYMBOL:- MFL

Scrip Code 543332

Dear Sir,

Sub.: Corporate Presentation

Ref.: Regulation 30 of SEBI (LODR) Regulations, 2015

We forward herewith Corporate Presentation of the Company.

The presentation will be shared to Investors for Virtual Conference / Investors Meet / Conference Call.

The aforesaid information is also being placed on the website of the Company.

Thanking you. For Epigral Limited (Formerly known as 'Meghmani Finechem Limited')

K. D. Mehta Company Secretary and Compliance Officer Membership No. FCS 2051

Epigral Limited (Formerly known as Meghmani Finechem Limited)

Epigral Tower, Behind Safal Profitaire Corporate Road, Prahladnagar Ahmedabad 380015 **T** +91 79 29709600 **E** info@epigral.com **W** epigral.com

CIN L24100GJ2007PLC051717

Epigral Limited (formerly known as Meghmani Finechem Ltd)

Corporate Presentation



Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Meghmani Finechem Limited (the "Company") solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company

Certain statements in this presentation concerning our future growth prospects are forward looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Risk and uncertainties relating to the statements include, but are not limited to, risks and uncertainties regarding fiscal policy, competition, inflationary pressures and general economic conditions affecting demand / supply and price conditions in domestic and international markets. The company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. The Company does not make any promise to update/provide such presentation along with results to be declared in the coming years.



Company Overview Founded: 2007 22% 30% 5 Year Revenue CAGR (FY23) 5 Year EBITDA CAGR (FY23) Employees: 900 +**0.8**x 32% Debt to Equity (FY23) ROCE (FY23) Capacity: Chlor-Alkali# – 421 KTPA CAGR 23% Derivatives# – 190 KTPA 5,000 Revenue from operations (₹ Cr) 2188 Certified: 1551 **Responsible Care Certificate** 829 710 611 Manufacturing facility: **FY19 FY18 FY21 FY22 FY23** Fully-integrated & automated complex **FY27E**


Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA

Derivatives : CPVC Resin – 30 KTPA, Epichlorohydrin – 50 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA





Rebranding




- Renaming is undertaken to strengthen the corporate brand in line with the company's commitment to transform the company as a global multi-product chemical conglomerate and enhance our reputation as an integral partner for esteemed clients and our stakeholders
- This is done through an inclusive process involving internal, external perspectives and engagement with multiple stakeholders



Diversified and integrated portfolio

Fully Integrated Product Portfolio






Import Substitution – Make in India

Diversified End User Industries

Sole Manufacturer of ECH in India

Diversifying Portfolio; De-Risking Business Model

Fully Integrated Complex





Our Values



Together, in caring and agile manner, we make it happen



Competitive Strength

Well Invested Infrastructure

- State of the art manufacturing facility
- Strategic location with close connectivity to ports and raw material availability.
- Large customer base within a 100 km radius

Well established brand

- Epigral is a known brand in Indian chemical market
- Serving domestic customers for last 12 Yrs
- Pan India reach through a wide network of distributors



Focused on Efficiency

- Low cost operations as fully backward and forward integration
- Fully automated complex
- Continuous addition of value added products



- Catering to more than 15 industries
- Revenue split is evened out among customer base
- o End user market growing rapidly

Underpinned by a Technically Qualified Leadership Team

Catering to high growth industries

Increased market potential & higher growth exposure




The addressable market for Epigral is growing ~10-13% in the next 5 years




Capacities

Manufacturing Plant Capacity (KTPA)



Expected Commissioning, * Commissioning date

Transitioning towards Derivatives & Specialty Chemicals



Revenue from the derivatives and specialty segment to be >60% by FY27E

Derivatives & Specialty – CPVC Resin, Epichlorohydrin, Chloromethanes and Hydrogen Peroxide Chlor-Alkali – Caustic Soda and Caustic Potash



Chlor-Alkali

Caustic Soda (NaOH)

India's NaOH Requirement: ~ 4,500 KTPA
Demand CAGR: ~ 8%



- o We are 4th largest producer in India
- Caustic Soda is basic raw material and caters to many industries. Major industries are alumina, textile, chemical, etc.
- Demand for Caustic Soda is expected to increase to 5.0 million ton by FY2025
- Co-products are key raw material for our value added downstream products (CMS, H2O2, ECH and CPVC)

Caustic Potash (KOH)

India's KOH Requirement: 94 KTPA
Demand CAGR: ~ 8%



- We are 3rd largest producer in India
- Caustic Potash is majorly consumed in soap & detergent, agrochemical and pharmaceutical industry
- The India's capacity stands at 83 KTPA
- Co-products are key raw material for our value added downstream products (CMS, H2O2, ECH and CPVC)



Derivative Products

Chloromethanes (CMS)

India's CMS Requirement: 580 KTPA
Demand CAGR: ~ 12%





PTFE Pipes



Refrigerant Gas

- We are 5th largest producer in India
- CMS plant produces 3 products, MDC, Chloroform and CTC. It is majorly drive by MDC
- The India's capacity stands at 677 KPTA
- CMS is used majorly in pharmaceutical, refrigerant, Tetrafluoroethylene (TFE), etc.

Hydrogen Peroxide (H2O2)

✤ India's H2O2 Requirement: 340 KTPA

Demand CAGR: ~ 10%



- We are 3rd largest producer in India
- H2O2 demand will continue to grow driven by diverse industrial uses – paper & pulp, textiles, effluent treatment, chemicals, etc.
- The India's capacity stands at 429 KTPA




Derivatives & Specialty Chemicals CPVC Resin

India's CPVC Requirement: 200 KTPA
Demand CAGR: ~ 13%







- o Largest producer in India
- Key raw material for heat resistant pipes
- Antidumping duty Imposition on Imports from China and Korea creating opportunity for domestic Market.
- Growing demand of CPVC in India for Pipe and Fittings in Chemical processing and Irrigation.
- 95% of CPVC resin demand was served through import (before Epigral commissioned its plant)

Epichlorohydrin (ECH)

India's ECH Requirement: 85 KTPA
Demand CAGR: ~ 15%



- 1st company in India to produce sustainable bio based ECH
- Domestic alternative for 100% imported product
- Competitive advantage due to captive raw materials
- Estimated Capex ₹ 270 Cr, with a capatily of 50 KTPA



Chlorotoluene & Value Chain

Project Details

- Capex for the project will be ₹ 180 Cr and expected revenue of Rs. 300 Cr
- Expected commissioning date: Q4FY24
- This facility will be forward integrated to our chloralkali facility
- **Range of products** will be manufactured through various reaction capabilities
- This will be intermediates for manufacturing pharmaceutical and agrochemical active ingredients

Rationale

- Foundation for the next phase of growth in Specialty Chemicals
- Chlorine is captive a raw material in line to strengthen fully integrated complex
- **1st in India to manufacture,** under the initiative of Make in India and Aatmanirbhar Bharat
- Facility will enable us to manufacture various reactions



Research & Development Centre

Project Details

- o Capex for the project will be ₹ 25 Cr
- A step towards strengthening presence in Specialty chemicals
- Location Changodar, Ahmedabad

Rationale

- R&D center will be used for creating further molecules for Chlorotoluene and other new molecules, which will be intermediates for pharmaceutical and agrochemical active ingredients
- R&D center will be helpful to create Chlorotoluene ecosystem/family and strengthen fully integrated facility
- It will help the company as whole to grow in Specialty Chemical post FY2024

EP GRAL

mbership Nov ICC_WR/RM/M_03

Focused on ESG

ENVIRONMENT

- o Focused on using best technology to manage critical resources, to moderate the consumption of energy and natural resources and drive operations efficiently
- Focus is to manufacture more from less, basis for environment responsibility
- Entered in JV to set up 18.34 MW Wind-Solar Hybrid Power Plant for internal consumption
- o Intend is to minimize effluents discharge while moderating water consumption
- First company to produce sustainable bio-based Epichlorohydrin
- o Safety protocols imbibing in the culture of the company and timely management review safety systems with quantified leading and lagging indicators

SOCIAL RESPONSIBILITY

RC Logo No: 0 Responsible Care UR COMMITMENT TO SUSTAINABILI MEGHMANI FINECHEM LTD ith permission to use the RC Logo alid from JUNE 2022 TO MAY 2025 🔆 icc Indian Chemical Council



- o Employees Investment in culture of excellence, timely training, scope for growth, talent investment, extensive safety provisions and supporting financially and mentally in difficult times
- Community Engaged community around manufacturing plant. Supporting them in difficult times. Deeply rooted CSR in the area of education, health & family welfare, sustainable livelihood, infrastructure and other social activities
- Customers and vendors Strong and long relation with customers and vendors. Over a period built on eco-system of vendors and primary customers

GOVERNANCE



- Experienced board with 8 of 10 are non-executive directors and 50% board is independent
- Each board committee is chaired by an Independent director
- o Focus on managing the business with all stakeholders in transparent manner
- o All the strategic decisions are taken considering interest of minority shareholders
- o Timely disclosure of material announcements



Growth Strategy

Forward & Backward Integration:

- Scale up capacities in existing products
- New value added products in existing value chains
- Improved market position

Opportunities in high growth sectors:

- Explore opportunities in various sectors
- Increase presence & improve market share
- Entering into products which are fully imported

New Value Chains:

- Expand chemistry expertise to enter new value chains (specialty chemicals)
- Addition of new reaction capabilities


Achieving economies of scale:

- Optimising existing complex
- Achieving efficiency operations to become a low cost producer

Vision – To achieve revenue of ₹ 5,000 Cr by FY2027




Financial Performance – P&L





Balance Sheet Ratios





Historic Income Statement

Particulars (₹ Cr)	FY19	FY20	FY21	FY22	FY23	
Total Revenue	720	613	831	1,555	2,196	
Gross Profit*	431	300	407	716	951	
Gross Margin (%)	61%	49%	49 %	46%	43%	
EBITDA	312	194	261	509	689	
EBITDA Margin (%)	44%	32%	32%	33%	31%	
Depreciation	54	44	74	86	109	
Finance Cost	25	11	29	44	66	
РВТ	242	141	161	383	523	
PAT	183	112	101	253	353	
PAT Margin (%)	25%	18%	12%	16%	16%	
EPS (₹)	25.1	27.0	24.3	60.8	85.0	



Historic Balance Sheet

Assets (₹ Cr)	FY21	FY22	FY23	Liabilities (₹ Cr)	FY21	FY22	FY23
Fixed Assets	1,228	1,657	1,962	Share Capital	42	42	42
Financial Assets	10	8	28	Reserves & Surplus	643	684	1,028
Other Non-current Assets	29	11	23	Long-Term Borrowings	340	557	396
Inventories	54	154	212	Redeemable Preference Shares	-	211	149
Trade Receivables	119	256	166	Other Non-current Liabilities	35	97	171
Cash & Bank Balances	1	25	15	Short Term Borrowings	75	221	332
Loans & Advances	0	0	0	Trade Payables	73	88	110
Other Current Assets	8	11	26	Other Current Liabilities	240	223	205
				Short Term Provisions	0	0	0
Total	1,449	2,124	2,432	Total	1,449	2,124	2,432

About us and Investor Contact

Epigral Ltd (formerly known as Meghmani Finechem Ltd), incorporated in 2007, is a leading integrated manufacturer of chemicals in India. The company has state of the art manufacturing facilities in Gujarat, Dahej – a leading PCPIR region in the country. Epigral's Dahej facility is a backward and forward integrated and automated complex with a wellestablished infrastructure and Captive Power Plants. In India, Epigral is the 1st to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is India's 4th largest manufacturer of Caustic Soda, Chlorine and Hydrogen and a leading manufacturer of Caustic Potash, Chloromethanes and Hydrogen Peroxide.

Epigral is strengthening its position in specialty chemical segment by expanding CPVC Resin capacity to 75,000 TPA, entering into Chlorotoluene & value chain and setting up R&D centre. The company is focused on sustainable value creation for all its stakeholders and has been awarded with the Responsible Care certificate.

For further information

Please log on to website www.meghmanifinechem.com

Milind Kotecha Investor Relations <u>milind.kotecha@meghmani.com</u>

Corporate Office

"Epigral Tower", B/h Safal Profitaire, Corporate Road, Prahladnagar, Ahmedabad 380015, Gujarat, India

Manufacturing Site

CH/1 and CH/2, GIDC Industrial Estate, Dahej, Tal. Vagra, Dist. Bharuch – 392130, Gujarat, India